Optimizing Specialty Pharmacy Practice in HER2-Altered Non-Small Cell Lung Cancer: Testing, Treatment, and Access

Program Description

HER2 alterations represent a distinct molecular subset of non-small cell lung cancer (NSCLC). While HER2 protein overexpression occurs in 10% to 15% of cases, HER2 mutations often occur independent of protein levels. Specialty and oncology pharmacists play a critical role in this landscape by ensuring comprehensive biomarker testing is completed, as molecular distinction is central to therapeutic selection from diagnosis to second-line and later sequencing. Recent clinical data and treatment approvals have introduced highly effective targeted therapies for patients with HER2-altered NSCLC. Throughout the program, attendees will follow a patient case to practice prioritizing diagnostic methodologies, identifying gaps in biomarker reports, and aligning results with evidence-based treatment sequencing. Critical considerations for comprehensive toxicity management, focusing on early detection of tyrosine-kinase inhibitor-associated diarrhea and antibody-drug conjugate-related interstitial lung disease, will also be discussed. Upon completion, specialty and oncology pharmacists will be equipped to support the multidisciplinary care team, improving patient adherence and navigating complex access challenges through expert counseling and proactive intervention.

Target audience: Specialty Pharmacist
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate among HER2 mutation subtypes in non-small cell lung cancer (NSCLC) and biomarker testing results to ensure appropriate patient selection for HER2-targeted therapy
• Use current guideline recommendations and emerging clinical trial evidence to determine appropriate HER2-targeted therapy for patients with NSCLC
• Identify specialty pharmacist-driven strategies for monitoring, preventing, and managing adverse effects associated with HER2-targeted therapies in NSCLC
• Apply strategies to navigate access barriers to HER2-targeted therapies in NSCLC